- Home
- STOK
as 02-21-2025 4:00pm EST
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | BEDFORD |
| Market Cap: | 556.7M | IPO Year: | 2019 |
| Target Price: | $23.83 | AVG Volume (30 days): | 799.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.28 - $17.58 | Next Earning Date: | 03-24-2025 |
| Revenue: | $16,742,999 | Revenue Growth: | 81.08% |
| Revenue Growth (this year): | 105.42% | Revenue Growth (next year): | 15.13% |
Stock Insider Trading Activity of Stoke Therapeutics Inc. (STOK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Skorpios Trust | STOK | 10% Owner | Dec 23 '24 | Sell | $11.50 | 2,000,000 | $23,000,000.00 | 6,906,181 | |
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Dec 9 '24 | Sell | $12.99 | 2,586 | $33,595.50 | 44,746 | |
| Kaye Edward M. MD | STOK | CEO | Dec 9 '24 | Sell | $12.99 | 6,786 | $88,158.28 | 61,885 | |
| Allan Jonathan | STOK | GENERAL COUNSEL & CORP SEC | Dec 9 '24 | Sell | $13.34 | 13,666 | $185,978.06 | 23,028 | |
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Dec 6 '24 | Sell | $12.78 | 13,945 | $178,182.24 | 44,746 | |
| Kaye Edward M. MD | STOK | CEO | Dec 6 '24 | Sell | $12.78 | 6,170 | $78,837.18 | 61,885 | |
| Allan Jonathan | STOK | GENERAL COUNSEL & CORP SEC | Dec 6 '24 | Sell | $12.78 | 9,696 | $123,890.64 | 23,028 | |
| Ticho Barry | STOK | CHIEF MEDICAL OFFICER | Dec 1 '24 | Sell | $12.07 | 10,000 | $120,698.00 | 44,746 |
Latest Stoke Therapeutics Inc. News
STOK Breaking Stock News: Dive into STOK Ticker-Specific Updates for Smart Investing
Pharmaceutical Technology
3 days ago
Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment
Benzinga
4 days ago
Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal
MT Newswires
4 days ago
HC Wainwright Adjusts Price Target on Stoke Therapeutics to $47 From $35, Maintains Buy Rating
MT Newswires
4 days ago
Biogen, Stoke Partner on Dravet Syndrome Investigational Drug Zorevunersen
Business Wire
4 days ago
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
BioPharma Dive
4 days ago
Biogen buys rights to Stoke’s rare epilepsy drug
Zacks
17 days ago
Strength Seen in Stoke Therapeutics (STOK): Can Its 9.4% Jump Turn into More Strength?
Simply Wall St.
a month ago
The 13% return this week takes Stoke Therapeutics' (NASDAQ:STOK) shareholders one-year gains to 116%
Compare STOK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "STOK Stoke Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.